Blood Cancers
Cancer Journey

Welcome Home Sidebar Block

 

 

VIDEO LIBRARIES

On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our first video welcomes all to the event, and it was our extreme pleasure to have Chris Draft and Dr. Ross Camidge join us to start the day! This is followed by keynote topic "Does NED matter? Using “curative” surgery or radiation techniques to treat "incurable" advanced lung cancer," with Dr. Rob Meguid, and a panel discussion featuring Dr. Meguid, Dr. Chad Rusthoven, Dr. Ross Camidge, and chaired by Dr. H. Jack West.

For our third video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss how NSCLC subtype (histology) can alter chemotherapy recommendations in advanced NSCLC.

For our second video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss what is the value of chemotherapy in advanced/metastatic NSCLC.

All of us at the Global Resource for Advancing Cancer Education are very excited to introduce our newest project - the GRACE Spanish Lung Cancer Library. This collection of videos with our Spanish speaking faculty will discuss the basics of lung cancer for Spanish speaking patients and caregivers. For our first video, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss what is adjuvant chemotherapy for early stage NSCLC and why it would be recommended.

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. John Kuruvilla...

ARTICLES

Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa). [powerpress]

A couple of weeks ago, I described the new concept of a "tweetchat" about lung cancer, and we're about to have our second of these tomorrow: Thursday...

Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as...

Afatinib, newly christened Gilotrif, is the newest EGFR tyrosine kinase inhibitor (TKI) approved by the FDA, specifically for patients with an EGFR...

Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients. [powerpress]

COMMUNITY FORUM

I've managed to survive Stage IV Lung Cancer for nine years; having been diagnosed with Stage I, 11 years ago, when I had the top part of my right...

Hi everyone, I'm very new to this forum so I tried my best to ask an appropriate question so forgive me if this is still too specific :) My father w/...

Stage lV Adenocarcinoma with Efgr and 80% pdl1 Had 5 radiation treatments to lung prior to start of trial. Received 4 treatments of drugs opdivo and...

Two and a half weeks ago, I had a robot-assisted upper left lung lobectomy, because of a 2 cm nodule, diagnosed to be Stage 1B lung cancer because of...

I was diagnosed with NSCLC lung adenocarcinoma last year and had lobectomy to remove RUL. Molecular testing shows ROS1 mutation. Is ROS1 mutation not...

Subscribe to Blood Cancers